Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Pathalys Pharma | $105M | 20 Aug 2024 | Raleigh, North Carolina, United States | ||
Renalys Pharma | $54M | 17 Jul 2024 | Tokyo, Kantō, Japan | ||
Arialys Therapeutics | $58M | 12 Sep 2023 | La Jolla, California, United States | ||
Pathalys Pharma | $150M | 18 Jan 2023 | Raleigh, North Carolina, United States | ||
Mineralys Therapeutics | $118M | 08 Jun 2022 | Radnor, Pennsylvania, United States | ||
Aculys Pharma | $25M | 28 Mar 2022 | Fujisawa, Kanagawa Prefecture, Japan | ||
Aculys Pharma | $3M | 28 Oct 2021 | Fujisawa, Kanagawa Prefecture, Japan | ||
Pathalys Pharma | $11M | 22 Jun 2021 | Raleigh, North Carolina, United States | ||
Mineralys Therapeutics | $40M | 06 Apr 2021 | Radnor, Pennsylvania, United States |
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Pathalys Pharma | $105M | 20 Aug 2024 | Raleigh, North Carolina, United States | ||
Renalys Pharma | $54M | 17 Jul 2024 | Tokyo, Kantō, Japan | ||
Arialys Therapeutics | $58M | 12 Sep 2023 | La Jolla, California, United States | ||
Pathalys Pharma | $150M | 18 Jan 2023 | Raleigh, North Carolina, United States | ||
Mineralys Therapeutics | $118M | 08 Jun 2022 | Radnor, Pennsylvania, United States | ||
Aculys Pharma | $25M | 28 Mar 2022 | Fujisawa, Kanagawa Prefecture, Japan | ||
Aculys Pharma | $3M | 28 Oct 2021 | Fujisawa, Kanagawa Prefecture, Japan | ||
Pathalys Pharma | $11M | 22 Jun 2021 | Raleigh, North Carolina, United States | ||
Mineralys Therapeutics | $40M | 06 Apr 2021 | Radnor, Pennsylvania, United States |